The litigation, spearheaded by Rosen Law Firm, centers on claims that Park Ha misled shareholders regarding its business operations and trading activity. According to the complaint, the company’s IPO was allegedly structured with an artificially low public float to enable a fraud involving social media misinformation and impersonated financial professionals. Plaintiffs assert that these undisclosed factors artificially inflated the stock price during the designated class period.
In section Releases
Investors Face September Deadline in Park Ha Securities Lawsuit
September 28, 2026, marks the final opportunity for investors who purchased Park Ha Biological Technology Co., Ltd. securities between December 27, 2024, and July 8, 2025, to apply as lead plaintiffs in a class action lawsuit alleging the company facilitated a complex stock manipulation scheme.

Investors who purchased shares during this timeframe may participate in the action through a contingency fee arrangement, meaning no out-of-pocket costs are required to join. While the court has not yet certified a class, those wishing to serve as lead representatives must file their motions by the September deadline. Individuals who choose not to serve as lead plaintiffs remain eligible to share in any potential future recovery without taking further action at this stage.
Comments (0)
No comments yet. Be the first!